Serum autoantibodies against components of nuclear dots (anti-NDs), namely PML and Sp100, are specifically detected in 20% to 30% of patients with primary biliary cirrhosis (PBC). Although anti-ND antibodies are nonpathogenic, the mechanisms that lead to this unique reactivity are critical to understanding the loss of immune tolerance in PBC. Importantly, Sp100 and PML are both covalently linked to small ubiquitin-related modifiers (SUMOs). Therefore, we investigated whether SUMO proteins are independent autoantigens in PBC and studied 99 PBC sera samples for reactivity against NDs, PML, and Sp100, as well as against SUMO-2 and SUMO-1 recombinant proteins. Autoantibodies against SUMO-2 and SUMO-1 were found in 42% and 15% of anti-ND-positive PBC sera, respectively. Anti-SUMO reactivity was not observed in anti-ND-negative sera. Anti-SUMO-2 autoantibodies were found in 58% of sera containing autoantibodies against both PML and Sp100 and were detected exclusively in sera containing anti-Sp100 autoantibodies. In conclusion, SUMO proteins constitute a novel and independent class of autoantigens in PBC. P rimary biliary cirrhosis (PBC) is an autoimmune disease of unknown etiology characterized by inflammatory destruction of the intrahepatic bile ducts and the presence of serum autoantibodies to mitochondrial antigens (AMAs) detected in approximately 90% to 95% of cases. 1 In contrast to AMAs, approximately 50% of patients with PBC have serum antinuclear autoantibodies (ANAs), 2 with the nuclear dot (ND) pattern found in 20% to 30% of cases and considered specific for PBC. 3 The pathogenic role of ANA in PBC is not clear, but understanding the process of development of these disease-specific autoantibodies appears to be important in the dissection of the mechanisms leading to autoimmunity in PBC. Autoantibodies to NDs react with large nuclear multiprotein complexes sharing several biological features, 4 including Sp100 5 and PML 6,7 proteins, as well as small ubiquitin-related modifiers (SUMOs). 8 Sp100 and PML constitute the main antigens for anti-ND ANA in PBC, with both proteins being targeted in the majority of patients with ANA-positive PBC. Interestingly, SUMO-1 and the related SUMO-2 and SUMO-3 proteins are unique among other ND proteins Abbreviations: PBC, primary biliary cirrhosis; AMA, antimitochondrial autoantibody; ANA, antinuclear autoantibodies; NDs, nuclear dots; SUMO, small ubiquitin-related modifier; IIF, indirect immunofluorescence; EGFP, enhanced green fluorescent protein; PBC, primary biliary cirrhosis; PML, promyelocytic leukemia protein. From the